查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363011

碳青霉烯类市场规模、份额和趋势分析报告：按药物类别、用途、配销通路、地区和细分市场预测，2023-2030

Carbapenem Market Size, Share & Trends Analysis Report By Drug Class (Meropenem, Imipenem, Ertapenem), By Application (UTI, Blood Stream Infections, Pneumonia), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 236 Pages | 商品交期: 2-10个工作天内

价格

碳青霉烯市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球碳青霉烯类市场规模将达到52.4亿美元，2023年至2030年年复合成长率为4.78%。

碳青霉烯类使用量的增加、抗生素处方率的增加以及由于研发进步而出现的新药是预计在预测期内推动市场成长的一些要素。

根据美国肺臟协会 2022 年 11 月发表的一篇论文，肺炎的流行程度比人们普遍认识的要高，年度导致超过 100 万人住院，5 万人死亡。 2023 年 5 月，Antavio 开始了一项 I 期研究，为健康志愿者给药第一给药抗生素治疗医院感染。该治疗方法被称为 MEM-ANT3310，将美罗培南 (MEM) 与 Antavio 的新型广谱丝氨酸 β-内酰胺酶抑制剂 ANT3310 结合。这将推动预测期内的市场成长。

此外，在大流行期间，世界各地的卫生系统在管理 COVID-19 重症病例方面面临巨大挑战，特别是在 ICU 环境中。许多重症 COVID-19 患者需要先进的医疗护理，包括使用抗生素来应对继发细菌感染。碳青霉烯类是强效广效抗生素，是这些患者细菌感染疾病的治疗选择之一。因此，COVID-19 大流行期间对市场产生了重大影响。

北美，特别是美国的药品法律规范非常完善，为药品核准提供了明确的途径。例如，2022年8月，布鲁克斯实验室及其子公司Brooks Steriscience获得美国食品药物管理局（USFDA）核准美罗培南注射液（每瓶500毫克、每瓶1克）产品，宣布被收购。本品为仿製药，相当于辉瑞公司的美瑞注射液。

然而，过度使用和滥用抗生素（包括碳青霉烯类）会导致抗菌素抗药性（AMR）的产生。随着细菌不断进化并对这些药物产生抗药性，它们治疗感染疾病的有效性将会下降，对碳青霉烯类和其他抗生素构成重大挑战。

碳青霉烯市场报告亮点

  • 按药物类别划分，美罗培南细分市场由于其对多种细菌（包括多重抗药性菌株）具有广谱活性，将在 2022 年占据市场主导地位。其他细分市场预计将以最快的年复合成长率成长。
  • 从用途来看，尿道感染（UTI）领域预计将在 2022 年占据最大的市场份额，并见证最快的成长速度。尿道感染被认为是全世界最常见的细菌感染疾病。
  • 从配销通路来看，由于细菌感染疾病患病不断上升，医院药房预计将在 2022 年占据市场主导地位，并以最快的年复合成长率成长。
  • 2022 年，由于主要市场参与者和强大的医疗基础设施的存在，北美主导了市场。因此，该地区的碳青霉烯市场预计在预测期内将扩大。
  • 由于印度和中国等开发中国家尿道结石患病、医疗支出增加以及医疗基础设施改善，亚太地区预计在预测期内将以最快的速度成长。

目录

第1章碳青霉烯市场：调查方法与范围

第2章碳青霉烯市场：执行摘要

  • 市场概述
  • 产品类型和用途概况
  • 配销通路简介
  • 竞争形势概览

第3章碳青霉烯类市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 市场动态
  • 市场促进因素分析
    • 抗生素抗药性感染疾病的传播
    • 临床研究的大量研发投资
  • 市场抑制因素分析
    • 碳青霉烯类生产成本高
    • 副作用和安全问题
  • 波特五力分析
  • PESTLE分析

第4章碳青霉烯类市场：药物类别估计与趋势分析

  • 碳青霉烯类市场：药物类别变异分析
  • 美罗培南
  • 亚胺培南
  • 厄他培南
  • 其他的

第5章碳青霉烯类市场：用途估算与趋势分析

  • 碳青霉烯类市场：用途变化分析
  • 尿道感染
  • 血流感染疾病
  • 腹腔内感染疾病
  • 肺炎
  • 其他的

第6章碳青霉烯类市场：配销通路估算与趋势分析

  • 碳青霉烯市场：配销通路波动分析
  • 医院药房
  • 零售药房
  • 其他的

第7章碳青霉烯市场：区域业务分析

  • 区域市场概述
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第8章碳青霉烯市场：竞争形势

  • 公司分类
  • 策略规划
  • 2022年主要企业市场占有率分析
  • 企业热力图分析
  • 公司简介
Product Code: GVR-4-68040-118-4

Carbapenem Market Growth & Trends:

The global carbapenem market size is expected to reach USD 5.24 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a CAGR of 4.78% from 2023 to 2030. The rise in the utilization of carbapenem-based antibiotics, elevated prescription rates of antibiotics, and progress in research and development resulting in the upcoming novel medications; are a few of the factors that are anticipated to propel the growth of the market over the forecast period.

According to an American Lung Association article, published in November 2022, Pneumonia is more prevalent than commonly perceived, leading to over a million hospitalizations and causing more than 50,000 deaths annually. In May 2023, Antabio initiated its Phase I trial by administering the initial dose of antibiotic therapy to healthy volunteers for hospital-acquired infections. The therapy, known as MEM-ANT3310, combines meropenem (MEM) with Antabio's novel broad-spectrum serine beta-lactamase inhibitor, ANT3310. This is fueling the growth of the market over the forecast period.

Moreover, during the pandemic, healthcare systems worldwide faced immense challenges in managing severe cases of COVID-19, especially in ICU settings. Many critically ill COVID-19 patients required advanced medical care, including the use of antibiotics to address secondary bacterial infections. Carbapenems, being potent broad-spectrum antibiotics, were one of the treatment options considered for bacterial co-infections in these patients. Thus, there was a significant impact during the period of the COVID-19 pandemic on the market.

The regulatory framework for pharmaceuticals in North America, particularly in the United States, is well-established and provides a clear pathway for drug approvals. For instance, in August 2022, Brooks Laboratories made an announcement stating that its subsidiary, Brooks Steriscience, has obtained approval from the United States Food & Drug Administration (USFDA) for the product, Meropenem Injection, available in 500mg per vial and 1gram per vial. This product serves as the generic equivalent to Pfizer Inc.'s Merrem Injection.

However, the overuse and misuse of antibiotics, including carbapenems, contribute to the development of antimicrobial resistance (AMR). As bacteria continue to evolve and become resistant to these drugs, their effectiveness in treating infections diminishes, posing a significant challenge for carbapenems and other antibiotics.

Carbapenem Market Report Highlights:

  • Based on drug class, the meropenem segment dominated the market in 2022, owing to their broad-spectrum activity against various bacteria, including multidrug-resistant strains. Other segment is anticipated to grow at the fastest CAGR rate
  • Based on application, the urinary tract infections (UTIs) segment held the largest share of the market in 2022 and is anticipated to grow at the fastest growth rate. UTIs are considered to be the most common bacterial infections across the globe
  • Based on the distribution channel, the hospital pharmacies segment dominated the market in 2022 and is anticipated to grow at the fastest CAGR rate owing to the rising prevalence of bacterial infections
  • In 2022, North America dominated the market, owing to the presence of major market players, and robust healthcare infrastructure. These are anticipated to boost the market for carbapenem in the region over the forecast period
  • Asia Pacific is anticipated to grow at the fastest growth rate over the forecast period due to the high prevalence of UTIs, growing healthcare spending, and the development of healthcare infrastructure in developing countries like India and China

Table of Contents

Chapter 1. Carbapenem Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Type Segment
      • 1.1.1.2. Drug Class Segment
      • 1.1.1.3. Application Segment
      • 1.1.1.4. Distribution Channel Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Carbapenem Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product Type and Application Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Carbapenem Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increasing prevalence of antibiotic-resistant infections
    • 3.4.2. High R&D investments in clinical research
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of production of carbapenem-based antibiotics
    • 3.5.2. Side effects and safety concerns
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. Carbapenem Market: Drug Class Estimates & Trend Analysis

  • 4.1. Carbapenem Market: Drug Class Movement Analysis
  • 4.2. Meropenem
    • 4.2.1. Meropenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3. Imipenem
    • 4.3.1. Imipenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Ertapenem
    • 4.4.1. Ertapenem Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Carbapenem Market: Application Estimates & Trend Analysis

  • 5.1. Carbapenem Market: Application Movement Analysis
  • 5.2. Urinary Tract Infections
    • 5.2.1. Urinary Tract Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Bloodstream Infections
    • 5.3.1. Bloodstream Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Intra-abdominal Infections
    • 5.4.1. Intra-abdominal Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Pneumonia
    • 5.5.1. Pneumonia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Carbapenem Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Carbapenem Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Carbapenem Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Carbapenem Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.5.4.2. Key Country Dynamics
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Carbapenem Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Carbapenem Market, 2018 - 2030 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Carbapenem Market: Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Product Type Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaborotion
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2022
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. The Menarini Group
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sun Pharmaceutical Industries Ltd
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Lupin
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Kopran Limited
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Aurobindo Pharma
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Daewoong Pharmaceuticals Co., Ltd.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Product Benchmarking
      • 8.5.7.3. Strategic Initiatives
    • 8.5.8. Shenzhen Haibin Pharmaceutical Co. Ltd.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Product Benchmarking
      • 8.5.8.3. Strategic Initiatives
    • 8.5.9. Merck & Co., Inc.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Venus Remedies Ltd
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 1 List of abbreviation
  • Table 2 North America carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 4 North America carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 7 U.S carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Canada carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Europe carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 13 Europe carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Europe carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 UK carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 UK carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 Germany carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 21 Germany carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 France carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 24 France carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Italy carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 Italy carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Spain carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Spain carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Denmark carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Denmark carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Sweden carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Sweden carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Norway carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Norway carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 China carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 China carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 46 China carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Japan carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 Japan carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 49 Japan carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 India carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 India carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 52 India carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 South Korea carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 South Korea carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 55 South Korea carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Australia carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 57 Australia carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 58 Australia carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Thailand carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 Thailand carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 61 Thailand carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Latin America carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 63 Latin America carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 Latin America carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Brazil carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 67 Brazil carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Mexico carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 70 Mexico carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 73 Argentina carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 Middle East & Africa carbapenem market, by country, 2018 - 2030 (USD Million)
  • Table 76 Middle East & Africa carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 Middle East & Africa carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 78 Middle East & Africa carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 80 South Africa carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 86 UAE carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE carbapenem market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait carbapenem market, by drug class, 2018 - 2030 (USD Million)
  • Table 89 Kuwait carbapenem market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait carbapenem market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global carbapenem market - Key market driver analysis
  • Fig. 7 Global carbapenem market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global carbapenem market - Porter's analysis
  • Fig. 10 Global carbapenem market - PESTEL analysis
  • Fig. 11 Global carbapenem market drug class outlook key takeaways
  • Fig. 12 Global carbapenem market: Drug class movement analysis
  • Fig. 13 Meropenem market estimates, 2018 - 2030 (USD Million)
  • Fig. 14 Imipenem market estimates, 2018 - 2030 (USD Million)
  • Fig. 15 Ertapenem market estimates, 2018 - 2030 (USD Million)
  • Fig. 16 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 17 Global carbapenem market application outlook key takeaways
  • Fig. 18 Global carbapenem market: application movement analysis
  • Fig. 19 Urinary tract infections market estimates, 2018 - 2030 (USD Million)
  • Fig. 20 Bloodstream infections market estimates, 2018 - 2030 (USD Million)
  • Fig. 21 Pneumonia market estimates, 2018 - 2030 (USD Million)
  • Fig. 22 Intra - abdominal infections market estimates, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 24 Global carbapenem market distribution channel outlook key takeaways
  • Fig. 25 Global carbapenem market: Test type movement analysis
  • Fig. 26 Hospital pharmacies market estimates, 2018 - 2030 (USD Million)
  • Fig. 27 Retail pharmacies market estimates, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates, 2018 - 2030 (USD Million)
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 Global carbapenem market: Regional movement analysis
  • Fig. 31 North America carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 34 Europe carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 35 UK carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 37 France carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 40 Denmark carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 41 Sweden carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 42 Norway carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 44 Japan carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 45 China carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 46 India carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 48 Australia carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 49 Thailand carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 54 MEA carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 57 UAE carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait carbapenem market, 2018 - 2030 (USD Million)
  • Fig. 59 Strategy framework